SRX Global Inc. — Form 8-K
Filed September 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
SRX Global Inc. (market cap ~$9.1M) has acquired senior secured debt from CERO Therapeutics Holdings, Inc. via a Consolidated Senior Secured Promissory Note dated August 27, 2026. Original principal: $5,666,108.77; maximum aggregate loan amount: $11,666,108.77 with up to $6,000,000 in additional advances. Interest accrues at 10% per annum (24.99% upon default); maturity October 15, 2026 (extendable 4×30 days). SRX is secured by CERo's T-cell therapy intellectual property (9 issued patents in US/Europe/Asia), all assets of CERo Therapeutics Inc. (subsidiary), and 100% equity pledge in CERo Therapeutics Inc. Holder may prepay only in connection with change of control; company must follow budget for advances.
Why this rating
Debt investment is ~129% of SRX's $9.1M market cap—exceptionally large relative to company size. Collateral includes valuable biotech IP portfolio (T-cell therapy patents through 2042). Materially affects capital structure and balance sheet. However, positioned as investment/revenue stream rather than operational transformation; repayment risk if CERo fails.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.56 ▲ 0.00% | at our read · unknown $1.56 | +10 min · unknown $1.56 ▲ 0.00% | +30 min · unknown $1.56 ▲ 0.00% | +1 hr · unknown $1.56 ▲ 0.00% | +4 hrs pending |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.